Immunotherapy is a critical and essential component of cancer care. However, its effectiveness differs from patient to patient. Moreover, there has been a constant debate on the implications of immunotherapy for cancer patients. Benign prostatic hyperplasia (BPH) is a common disease that affects men 50 years of age and above. Surgery is a commonly used treatment; however, significant advances in the medical field have opened pharmaceutical interventions to treat BPH.
Chronic kidney disease (CKD) is a serious and progressive condition associated with significant patient morbidity. Despite various interventions, kidney failure has also been a common outcome of CKD. Recently, SGLT2 inhibitors have been shown to slow down the progression of CKD. Join our exclusive webinar on “ Immunotherapy, Benign Prostatic Hyperplasia, and Kidney Disease Management ” with our experts on 25 th April…
